Health Condition 1: null- Chronic skin ulcers
Conditions
Interventions
Intervention1: SUCRALFATE WITH MUPIROCIN: Topical mupirocin 2% with Sucralfate 7% to be applied 3 times daily for 6 weeks or until ulcer healing whichever is earlier
Control Intervention1: MUPIROCIN:
Sponsors
Strassenburg Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either sex of age > 18 years Patients having grade 1 and grade 2 ulcer according to Wagner grading system. Ulcer of duration > 4 weeks. Wagner grading system A Grade 1 Superficial ulcer B Grade 2 Ulcer extension 1. Involves ligament, tendon, joint capsule or fascia 2. No abscess or osteomyelitis C Grade 3 Deep ulcer with abscess or osteomyelitis D Grade 4 Gangrene E Grade 5 Extensive gangrene
Exclusion criteria
Exclusion criteria: Female patients who are pregnant or breast-feeding. Patients having ulcer grade >2 according to Wagner grading system Ulcer of duration > 6 months. Patients diagnosed to have decubitus ulcer. Patients diagnosed to have ulceration due to malignancy. Patients who have used formulations containing mupirocin or sucralfate for their ulcer within the last 4 weeks. Patients with history of hypersensitivity to formulations containing mupirocin or sucralfate. Patients suffering from debilitating chronic diseases including frankly uncontrolled diabetes and advanced malignancy. Patients suffering from frankly immunocompromising disorders such as HIV/AIDS. Patients on systemic antimicrobials, corticosteroids or any other medication known to influence wound healing currently or within last 4 weeks. Patients suffering from alcoholism, substance abuse or psychiatric disorders that are liable to make them unreliable trial subjects. Patients without adequate caregiver support at home who can supervise application of medication. Any other condition which, in the opinion of the investigators, is likely to substantially increase the risk of non-adherence or the possibility of confounding of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in ulcer area from baseline. Number of subjects achieving at least or more than 50% reduction in ulcer area . Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Ulcer qualitative parameters on a 3 point scale â?? Wound infection score.Timepoint: day0,3 weeks,6 weeks | — |
Countries
India
Contacts
Public ContactDr Subhrangsu Chatterjee
Institute of Postgraduate Medical Education & Research, Kolkata â?? 700020
Outcome results
None listed